 - To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product IMP related dose limiting toxicities DLTs to determine the recommended dose RD of SAR408701 in Japanese patients with advanced malignant solid tumors dose-escalation part. 